Navigation Links
Argos Therapeutics to Present Recent Clinical Developments and Corporate Overview at 18th Annual BioPartnering Europe
Date:10/8/2010

DURHAM, N.C., Oct. 8 /PRNewswire/ -- Argos Therapeutics today announced that Jeff Abbey, the company's president and chief executive officer, will present recent clinical developments and a corporate overview at the 18th Annual BioPartnering Europe conference in London at 12:15 p.m. BST on Monday, Oct. 11, 2010. The conference will take place at the Queen Elizabeth II Conference Centre.

Argos recently presented favorable progression-free survival and safety results from an ongoing Phase 2 trial for its Arcelis immunotherapy for renal cell carcinoma, AGS-003, in combination with sunitinib. The company anticipates the initiation of a large, randomized and controlled clinical study for AGS-003 in combination with sunitinib in 2011.

About the Arcelis™ Technology

Arcelis is Argos' proprietary technology for personalizing RNA-loaded dendritic cell immunotherapies for cancer, HIV and other infectious diseases. This platform is based on optimizing a patient's own (autologous) dendritic cells to trigger a tumor- or pathogen-specific immune response. To address the challenge of the unique genetic profile of each patient's disease and the genetic mutations of that disease, Argos loads the autologous dendritic cells with a sample of messenger RNA isolated from the patient's disease. Through this process, dendritic cells can potentially prime immune responses to the entire antigenic repertoire, resulting in an immunotherapeutic that is customized to the patient's specific disease.

About Argos Therapeutics, Inc.Argos is an immunotherapy company developing new treatments for cancer, infectious and autoimmune diseases and transplantation rejection. The Company has generated multiple platform technologies and a diverse pipeline of products based on its expertise in the biology of dendritic cells — the master switch that turns the immune system on or off. www.argostherapeutics.comContacts:David Schull or Andreas MarathovouniotisRusso Partners LLC(212) 845-4271 or (212) 845-4235david.schull@russopartnersllc.com or andreas.marathis@russopartnersllc.comJeff AbbeyArgos Therapeutics(919) 287-6308jabbey@argostherapeutics.com
'/>"/>

SOURCE Argos Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Results From Argos Therapeutics Arcelis™ Immunotherapy Phase 2 Study for Treatment of Renal Cell Carcinoma (RCC) Accepted for Poster Presentation at Ninth International Kidney Cancer Symposium
2. Michael R. Bristow, M.D. Ph.D. Joins Nile Therapeutics Scientific Advisory Board
3. Halozyme Therapeutics to Host Analyst Meeting on October 14 in New York
4. Prime Therapeutics Hires Peter Wickersham, Senior Vice President Cost of Care
5. Osseon® Therapeutics Introduces New Osseoflex® DR Steerable Bone Drill
6. Weikang Bio-Technology Plans to Launch New Therapeutics in First Quarter 2011
7. New American Therapeutics Acquires Antiviral Drug Denavir®
8. Nile Therapeutics to Present at BIO Investor Forum
9. Orexigen® Therapeutics to Speak at Fifth Annual JMP Securities Healthcare Conference
10. Echo Therapeutics to Present at the JMP Securities Healthcare Conference
11. Precision Therapeutics President and CEO Sean McDonald Recognized as a Leading Business Executive and Recipient of 2010 Pacesetters Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... The new report "Global Anti-Bacterial Drugs Market Assessment & Forecast: 2015 ... that the North America continued to lead ... that translated into revenues worth US$ 16,907.3 million. ... Asia-Pacific , Latin America , ... global anti-bacterial market is inclined towards North America ...
(Date:2/8/2016)... , Feb.8, 2016 Alzheimer Diagnostic ... Summary Medical Devices sector report , ... 2015" provides an overview of Alzheimer Diagnostic Tests ... comprehensive information on the pipeline products with comparative ... development. The report reviews major players involved in ...
(Date:2/8/2016)... , Feb. 8, 2016  Labvantage Lx, a ... its first male sexual enhancement product, EnduramenT. Setting ... proven ethnobotanicals with a patented biomedical breakthrough molecule ... the chemical compound responsible for many biological functions ... Forgoing the use of prescription ...
Breaking Medicine Technology:
(Date:2/9/2016)... ... , ... On January 12, 2016 Paul McElwee, a CroppMetcalfe HVAC technician, visited ... not producing any heat. Shortly after entering the home, Paul was able to identify ... levels of carbon monoxide into the home, at 2,000 parts per million in the ...
(Date:2/9/2016)... , ... February 09, 2016 , ... Dr. Rassouli, ... packages. Teeth whitening is among the most popular cosmetic procedures in dentistry today, but ... needs. This can put them at risk of teeth whitening-related damage. For a limited ...
(Date:2/9/2016)... Florida (PRWEB) , ... February 09, 2016 , ... ... cold therapy products, announced today the introduction of the newly designed, innovative shoulder ... comfort and better cold therapy coverage for the injured arm and shoulder to ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... and sealing company , is proud to announce that many of their franchises ... of customer service. The hard surface restoration franchises received customer recognition through positive ...
(Date:2/9/2016)... ... February 09, 2016 , ... The ... been won. A team from 21st Century Medicine (21CM) ( http://www.21cm.com/ ), ... the delicate neural circuits of an intact rabbit brain for extremely long-term storage ...
Breaking Medicine News(10 mins):